NOVO · Novo Integrated Sciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $13.29M | $12.57M | $11.74M | $9.31M | $7.86M | $9.42M |
| Cost of Revenue | $7.55M | $7.62M | $6.94M | $5.48M | $4.80M | $5.90M |
| Gross Profit | $5.74M | $4.95M | $4.80M | $3.82M | $3.06M | $3.52M |
| R&D | - | - | - | - | - | - |
| SG&A | $14.04M | $13.49M | $14.36M | $8.09M | $7.29M | $4.02M |
| Total Operating Expenses | $15.82M | $13.51M | $29.83M | $8.20M | $7.32M | $4.31M |
| D&A | $2.26M | $2.30M | $3.02M | $1.72M | $1.45M | $97.1K |
| Operating Income | ($10.08M) | ($8.55M) | ($25.03M) | ($4.37M) | ($4.26M) | ($785.6K) |
| Interest Expense | $652.4K | $360.6K | $1.59M | $165.0K | $156.7K | - |
| Income Tax | - | - | ($22.3K) | - | - | - |
| Net Income | ($16.17M) | ($13.21M) | ($32.85M) | ($4.46M) | ($4.92M) | ($392.0K) |
| EPS - Basic | ($0.89) | ($1.30) | ($0.18) | - | - | - |
| EPS - Diluted | ($0.89) | ($1.30) | - | - | - | - |
Balance Sheet
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $844.6K | $416.3K | $2.18M | $8.29M | $2.07M | $2.08M |
| Accounts Receivable | $1.92M | $1.47M | $1.02M | $1.47M | $1.73M | $1.46M |
| Inventory | $1.00M | $1.11M | $879.0K | $339.4K | - | - |
| Accounts Payable | $3.24M | $3.51M | $1.80M | $1.45M | $883.8K | $1.14M |
| Current Assets | $5.41M | $4.39M | $5.73M | $11.13M | $4.29M | $4.10M |
| Total Assets | $32.14M | $35.56M | $40.87M | $61.96M | $35.39M | $32.27M |
| Current Liabilities | $14.58M | $7.90M | $14.07M | $8.46M | $2.60M | $3.03M |
| Long-term Debt | $157.7K | $342.4K | $161.5K | $9.62M | - | - |
| Total Liabilities | $17.53M | $11.06M | $18.83M | $18.15M | $5.82M | $6.73M |
| Stockholders' Equity | $14.89M | $24.82M | $22.31M | $43.86M | $29.62M | $25.58M |
| Retained Earnings | ($83.20M) | ($67.03M) | ($53.82M) | ($20.97M) | ($16.51M) | ($11.59M) |
Cash Flow
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($5.07M) | ($2.24M) | ($5.88M) | ($1.02M) | ($441.7K) | ($822.3K) |
| Investing Cash Flow | ($5.0K) | ($49.2K) | $163.5K | $3.00M | $657.1K | ($842.9K) |
| Financing Cash Flow | $4.99M | $763.9K | ($427.1K) | $4.32M | ($271.7K) | $3.07M |
| CapEx | $5.0K | $49.2K | $190.2K | $255.9K | $12.1K | $107.6K |
| Free Cash Flow | ($5.07M) | ($2.29M) | ($6.07M) | ($1.28M) | ($453.8K) | ($929.9K) |
Ratios
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 43.2% | 39.4% | 40.9% | 41.1% | 38.9% | 37.4% |
| Operating margin | -75.8% | -68.0% | -213.2% | -47.0% | -54.2% | -8.3% |
| EBITDA margin | -58.8% | -49.7% | -187.5% | -28.5% | -35.8% | -7.3% |
| Net margin | -121.6% | -105.1% | -279.9% | -48.0% | -62.5% | -4.2% |
| Free cash flow margin | -38.2% | -18.2% | -51.7% | -13.8% | -5.8% | -9.9% |
| FCF / Net income | 0.31 | 0.17 | 0.18 | 0.29 | 0.09 | 2.37 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 105.6% | 107.3% | 122.4% | 86.9% | 92.7% | 42.7% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -50.3% | -37.2% | -80.4% | -7.2% | -13.9% | -1.2% |
| Return on equity | -108.6% | -53.3% | -147.3% | -10.2% | -16.6% | -1.5% |
| Return on invested capital | - | - | -88.0% | - | - | - |
| Liquidity | ||||||
| Current ratio | 0.37 | 0.56 | 0.41 | 1.32 | 1.65 | 1.35 |
| Quick ratio | 0.30 | 0.42 | 0.34 | 1.28 | 1.65 | 1.35 |
| Cash ratio | 0.06 | 0.05 | 0.15 | 0.98 | 0.80 | 0.69 |
| Leverage | ||||||
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.22 | - | - |
| Debt / Assets | 0.00 | 0.01 | 0.00 | 0.16 | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -15.4x | -23.7x | -15.7x | -26.5x | -27.2x | - |
| Equity multiplier | 2.16 | 1.43 | 1.83 | 1.41 | 1.19 | 1.26 |
| Liabilities / Assets | 0.55 | 0.31 | 0.46 | 0.29 | 0.16 | 0.21 |
| Efficiency | ||||||
| Asset turnover | 0.41 | 0.35 | 0.29 | 0.15 | 0.22 | 0.29 |
| Inventory turnover | 7.55 | 6.88 | 7.89 | 16.15 | - | - |
| Days sales outstanding | 53d | 43d | 32d | 58d | 80d | 57d |
| Days inventory outstanding | 48d | 53d | 46d | 23d | - | - |
| Days payable outstanding | 156d | 168d | 95d | 97d | 67d | 71d |
| Cash conversion cycle | -55d | -73d | -17d | -16d | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 5.7% | 7.1% | 26.1% | 18.4% | -16.6% | 18.3% |
| Revenue CAGR (3y) | 12.6% | 16.9% | 7.6% | 5.3% | 3.1% | - |
| Revenue CAGR (5y) | 7.1% | 9.6% | 10.3% | - | - | - |
| Gross profit growth (YoY) | 15.9% | 3.2% | 25.5% | 25.0% | -13.1% | 2.8% |
| Operating income growth (YoY) | -17.8% | 65.8% | -472.2% | -2.6% | -442.6% | 49.9% |
| Net income growth (YoY) | -22.3% | 59.8% | -636.2% | 9.2% | -1153.9% | 81.4% |
| EPS growth (YoY) | 31.5% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -121.4% | 62.3% | -374.3% | -182.2% | 51.2% | 6.0% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -40.0% | 11.3% | -49.1% | 48.1% | 15.8% | 12603.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-08-31.
Business segments
$13.29M totalHealth Care Services$8.30M · 62.4%
Product Sales$4.92M · 37.0%
Corporate$78.3K · 0.6%
Stability scores
Altman Z′
FY 2024 · bankruptcy risk
-2.60
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2024 · 9-point quality
4/9
Neutral
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Engines & Turbines
Comparing Novo Integrated Sciences against the 5 most active filers in the same SIC group.